<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940133</url>
  </required_header>
  <id_info>
    <org_study_id>PQR309-001</org_study_id>
    <secondary_id>2013-003441-42</secondary_id>
    <nct_id>NCT01940133</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309</brief_title>
  <official_title>Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PIQUR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PIQUR Therapeutics AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I, open label study to determine the Maximum Tolerated Dose(MTD) and&#xD;
      the Recommended Phase II Dose (RP2D) in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D)</measure>
    <time_frame>In average 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine overall safety</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of SAEs, incidence and severity of all AEs, changes of vital signs, physical examinations, body weight, changes of routine laboratory assessments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>PQR309</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Different dose evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PQR309</intervention_name>
    <description>Dosing will be orally, once a day for the duration of the trial.</description>
    <arm_group_label>PQR309</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of advanced solid tumor for which&#xD;
             no therapy of proven efficacy is available.&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Evidence of tumor progression with measurable or evaluable disease.&#xD;
&#xD;
          -  Use of adequate contraceptive measures for male patients.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant anticancer therapy (e.g., chemotherapy, radiotherapy, hormonal,&#xD;
             immunotherapy, biological response modifier, signal transduction inhibitors)&#xD;
&#xD;
          -  Patients with a history of myocardial infarction or coronary artery bypass within the&#xD;
             last 3 years.&#xD;
&#xD;
          -  Patients with severe/unstable angina, coronary/peripheral arterial bypass, symptomatic&#xD;
             congestive heart failure NYHA Class 3 or 4, hypertension BP&gt;150/100mmHg.&#xD;
&#xD;
          -  Pre-diagnosed diabetes mellitus.&#xD;
&#xD;
          -  Fasting glucose &gt; 7.0 mmol/L or HbA1c &gt; 6%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Wicki, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

